Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02. Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On December8, 2016, Esperion Therapeutics,Inc. (Company)
entered into a Scientific Advisor Agreement (the Advisor
Agreement) with Roger Newton, Ph.D. to which Dr.Newton will
retire from his role as the Companys Executive Chairman and Chief
Scientific Officer and transition into the role of Scientific
Advisor. The Advisor Agreement provides, among other things, that
Dr.Newton shall (i)transition to the role of Scientific Advisor
to the Company effective as of the start date of the Advisor
Agreement; (ii)receive a base salary of $120,000 per year while
serving as Scientific Advisor to the Advisor Agreement;
(iii)continue to be eligible for employee benefits under the
Companys plans and programs; and (iv)continue to vest in his
outstanding equity awards while continuing to provide services to
the Company, to the terms of his existing equity awards.Upon
transitioning to the role of Scientific Advisor, Dr.Newton will
cease to be an executive officer of the Company but will remain a
member of the Board of Directors of the Company.
The above description of the Advisor Agreement does not purport
to be complete and is qualified in its entirety by the terms of
the Advisor Agreement, a copy of which is attached as Exhibit10.1
hereto and incorporated herein by reference.
Item9.01 Financial Statements and Exhibits.
(d)Exhibits
|
ExhibitNo. |
|
Description |
|
10.1 |
Advisor Agreement, dated December8, 2016, between the |
About Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors. Esperion Therapeutics, Inc. (NASDAQ:ESPR) Recent Trading Information
Esperion Therapeutics, Inc. (NASDAQ:ESPR) closed its last trading session up +0.03 at 12.25 with 165,669 shares trading hands.